TY706 Crystal Form A Stability via Controlled Crystallization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The existing form of the compound TY706 is unstable in appearance and purity, making it unsuitable for direct use as a pharmaceutical raw material due to fluctuations in physical form and purity levels during solvent evaporation, which complicates its use in treating gout and hyperuricemia.

Innovation Solution

A stable crystal form (crystal form A) of TY706 is developed, characterized by specific X-ray diffraction peaks and DSC analysis, which is produced through refluxing the compound in a solvent and subsequent cooling and filtration, ensuring consistent appearance and high purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If the compound TY706 is separated from solution by evaporation of solvent, then the compound can be obtained in solid form, but the physical form and appearance fluctuate from batch to batch making it difficult to maintain constant state

Engineering Contradiction:
Improvesolid form obtentionVSAvoidappearance stability
Core Design Contradiction:
Ease of manufactureVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by controlling crystallization conditions including solvent type, temperature, pH value, and addition rate to obtain a stable crystal form (Form A) of TY706. This resolves the contradiction by transforming the amorphous or fluctuating solid obtained by simple evaporation into a well-defined crystal structure with consistent appearance and properties across batches.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent utilizes phase transitions through controlled crystallization from solution to transform the compound from an amorphous or unstable solid state into a stable crystal form. The crystallization process involves nucleation and crystal growth phases that produce consistent physical form and appearance, resolving the batch-to-batch variability issue.

Inventive Principle:
Principle #36Phase transitions

2Productivity

If the compound TY706 is separated from solution by evaporation of solvent, then the compound can be obtained quickly, but the purity of the solid fluctuates greatly making pharmaceutical raw material preparation difficult

Engineering Contradiction:
Improveobtention speedVSAvoidpurity consistency
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies preliminary action by performing crystallization before final product isolation. The crystallization step pre-purifies the compound by incorporating impurities into the mother liquor rather than having them co-evaporate with the product. This preliminary purification action ensures high and consistent purity while maintaining efficient production.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The crystallization process exploits phase transitions to separate the pure compound from impurities. As the solution cools or solvent evaporates during controlled crystallization, the pure compound crystallizes out while impurities remain in solution, achieving both high purity and consistent quality across batches.

Inventive Principle:
Principle #36Phase transitions

3Stability of the object's composition

If a stable crystal form is developed through controlled crystallization, then appearance and purity are maintained consistently, but additional processing steps are required

Engineering Contradiction:
Improveappearance consistencyVSAvoidprocess steps
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent merges the purification and form stabilization steps into a single crystallization operation. The controlled crystallization process simultaneously achieves impurity removal, consistent appearance, and stable physical form, eliminating the need for separate purification and drying steps that would otherwise be required.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent optimizes crystallization parameters (solvent selection, temperature profile, pH control, addition rate) to achieve stable crystal formation in a single step. By carefully controlling these parameters, the process achieves both purification and form stabilization without requiring multiple sequential operations, thus limiting the increase in process complexity.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The crystal form A of TY706 maintains stability over multiple batches, exhibits high purity, and demonstrates improved storage stability, making it suitable for pharmaceutical use with enhanced industrial practicality and efficacy in treating gout and hyperuricemia.

Implementation Method 1

A stable crystal form (crystal form A) of TY706 is developed, characterized by specific X-ray diffraction peaks and DSC analysis, which is produced through refluxing the compound in a solvent and subsequent cooling and filtration

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Implementation Method 2

its powder X-ray diffraction (PXRD) pattern expressed by 2θ degree using Cu-Kα radiation has diffraction peaks at 18.432±1, 19.846±1, 20.207±1, 20.327±1, 22.341±1, 22.735±1, 25.654±1, 26.119±1, 26.617±1 and 33.159±1

Methodology Applied
Scientific EffectX-ray diffraction: X-Ray

Implementation Method 3

The differential scanning calorimetry (DSC) analysis curve of the crystal form A of the compound TY706 of the present invention has an endothermic peak at 189.30° C.

Methodology Applied
Scientific EffectDifferential scanning calorimetry: Calorimetry

Data Source

PatentUS11149013B2Crystal form of urate transporter 1 inhibitor and preparation method and use thereof
Publication Date: 2021.10.19 TIANJIN INSTITUTE OF PHARMA RESEARCH CO LTD
  • US11149013B2 patent drawing
  • US11149013B2 patent drawing
  • US11149013B2 patent drawing

AI summary

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.